In Piazza con Marino - A tribute event to Marino
Fondazione Golinelli organizined, on Saturday, February 17, a special day to pay tribute to Marino Golinelli, philanthropist, entrepreneur, researcher and art lover...
Read more
Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million
Bologna, 31 January 2024, 22:01 CET – Alfasigma S.p.A. is pleased to announce the successful completion of the transaction to acquire the Jyseleca® (filgotinib) business from Galapagos NV (Euronext...
Read more
Alfasigma signs an agreement to acquire Jyseleca® business for up to €170 million from Galapagos following October letter of intent
Alfasigma S.p.A today announced that it has signed an agreement with Galapagos NV (Euronext & NASDAQ: GLPG) to acquire the Jyseleca® (filgotinib) business for up to €170 million....
Read more
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiar...
Read more
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.
Bologna, Italy – November 8, 2023 — Alfasigma S.p.A. (“Alfasigma”) announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. (“Interstellar”), successf...
Read more
Alfasigma signs a letter of intent to acquire the Jyseleca® business from Galapagos, expanding its European presence through an innovative product specializing in the rheumatology and gastrointestinal areas
Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company headquartered in Italy, announced today that it has signed a letter of intent to acquire the Jyseleca® business from Galapagos (Euronex...
Read more
Alfasigma S.p.A. tender offer for Intercept Pharmaceuticals, Inc. commences
Bologna, Italy– October 11, 2023 — Alfasigma S.p.A. (“Alfasigma”) today announced that its wholly-owned subsidiary, Interstellar Acquisition Inc., a Delaware corporation (“Purchaser”), has...
Read more
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Bologna, Italia e Morristown, New Jersey, Stati Uniti d’America – 26 settembre 2023 - Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceutic...
Read more
CARE&GO: Alfasigma's tips for summer!
CARE&GO is Alfasigma's innovative summer social campaign, which will accompany travelers during the summer period, giving advice easy to put into practice everyday....
Read more
Connecting the Dots: innovation and collaboration at the heart of the Global Leadership Meeting
Connecting the Dots was the main topic of the third Global Leadership Meeting held in Barcelona on 28th – 30th of June. An important milestone in the company’s journey to outline and reach its ful...
Read more